Це відео не доступне.
Перепрошуємо.
What is the role of CDK4/6 inhibitors in early breast cancer?
Вставка
- Опубліковано 10 сер 2023
- Michael Gnant, MD, FACS, FEBS, Medical University of Vienna, Vienna, Austria, gives an overview of current CDK4/6 inhibitors in early breast cancer. Recent trials such as the Phase II NATALEE trial (NCT03701334) of ribociclib plus endocrine therapy, the Phase II monarchE trial (NCT03155997) of abemaciclib and the Phase III Penelope-B trial (NCT01864746) of palbociclib have all demonstrated promising results. Prof. Gnant additionally talks on the PHERGain trial (NCT03161353) of dual HER2 blockade in early breast cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.